BIO-Key International

BIOkey reported an adjusted loss of $0.56 per share for Q2/2026, beating expectations, while revenue of $1.92 million missed the consensus of $2.2 million. Gross margins and licensing income rose significantly, and net loss narrowed 51% year over year, but a delayed large order and a warrant financing weighed on the market reaction. The stock fell about 12%; management expects profitability in H2/2026 and sees growth potential in Passkey:YOU, PortalGuard 7.0 and in EMEA/Middle East. » Altro su de.investing.com

BIO key reported Q2 revenue of USD 1.9 million (up 13%) and a halved net loss of USD 577,000. License revenues rose 53% to USD 1.2 million, while hardware sales fell 19%; expected hardware sales of about USD 800,000 were pushed into H2 2026. Gross margin improved to 87%; cash balance increased to over USD 4.5 million following the exercise of warrants. The company announced several customer contracts (including Saudi Arabia, Portugal, Jordan) and completed a 1:10 reverse stock split, restoring NASDAQ listing requirements. » Altro su de.investing.com

BIO-key received a reprimand from Nasdaq for noncompliance with Rule 5250(c)(1) after the quarterly report (Form 10-Q) for the period ended March 31, 2026 was not filed with the SEC on time. The Nasdaq Hearing Panel will take the violation into account when deciding on the company’s continued listing on the Nasdaq Capital Market. The stock has fallen 41% over the past six months and is currently trading at $4.10 with a market capitalization of about $4.45 million; InvestingPro rates the financial position as “WEAK” with a score of 1.67, but sees possible undervaluation. » Altro su de.investing.com

For the quarter ended March 31, 2026, Bio-Key International reported a loss per share of $0.15, compared with -$1.60 in the year-ago quarter. Revenue rose to $2.2 million from $1.6 million a year earlier. » Altro su finanzen.net

Nasdaq has suspended trading in BIO-key shares; starting Wednesday the company will trade under the same ticker on the OTC market. The suspension stems from failure to meet two listing requirements (minimum closing price of $1 over ten trading days and an outstanding Form 10-K). BIO-key announced a hearing to seek relisting, recently completed a 1-for-10 reverse stock split, and forecasts $5 million in revenue for H1 2026 and a return to profitability, but most recently reported an annual loss of $4.59 million and a sharp share-price decline. » Altro su de.investing.com